Through its Johnson & Johnson Medical GmbH affiliate in Germany, Johnson & Johnson Medical Devices (JNJ) is acquiring Emerging Implant Technologies (EIT), a manufacturer of 3D-printed titanium interbodies for spinal fusion.
Financial terms were not disclosed.
EIT’s 3D-printed devices address anterior, transforaminal and posterior lumbar fusion and cervical procedures. Implants are manufactured from EIT Cellular Titanium® that yields a porosity of 80% and are designed to mimic trabecular bone structure (obviating the need for bone graft) and address clinical shortcomings such as non-fusion, biocompatibility, subsidence, migration and image distortion.
EIT entered the U.S. market in 4Q17. In 1Q18, EIT gained FDA clearance to expand use of its Cervical Cage to multiple contiguous cervical levels (C2 to T1). This is reportedly the first multi-level 3D printed cervical cage on the U.S. market. Ex-U.S, EIT's products have been used in >10,000 procedures in >15 countries, including Australia, France, Germany, Korea and the Netherlands.
EIT’s portfolio includes:
- EIT Anterior Lumbar Interbody Decompression and Fusion Implant
- EIT Transforaminal Lumbar Interbody Decompression and Fusion Implant
- EIT Cervical Implant
- EIT Posterior Lumbar Interbody Decompression and Fusion Implant
This acquisition is in line with recent comments by JNJ CEO Alex Gorsky, who, in the company’s 2Q earnings call, said that JNJ is “very, very focused on getting [DePuy Synthes’ spine] business turned around and move it in the right direction.”
For 1H18, ORTHOWORLD estimated DePuy’s spine revenue at $719.5MM, -9.2% vs. 1H17.
Leadership stated that EIT’s technology complements DePuy’s recent introductions of the CONCORDE LIFT Expandable interbody, and in the U.S., the PROTI 360°™ interbody fusion devices, designed to treat degenerative disc disease.
Sources: Johnson & Johnson Medical Device Companies; ORTHOWORLD, Inc.; image courtesy of EIT